Cite

HARVARD Citation

    Yadav, V. et al. (2012). Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune diseases. p. . [Online]. 
  
Back to record